Sustained generic pricing pressure
Generic API business faces ongoing pricing erosion, with no improvement expected in the next two quarters, potentially impacting margins.
DIVISLAB / bear-case history
Track the concerns that keep returning.
Divi's Laboratories · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
high
Regulatory delays in new project validations
Commercialization of three major capex projects depends on regulatory approvals (EU, US), which could be delayed, pushing revenue contribution beyond 1-2 years.
Competition from new CDMO entrants
Analyst raised concern about increased competition in custom synthesis from Indian players; management acknowledged but emphasized long-term relationships and non-price factors.
US tariff impact on raw material costs
Management noted potential cost increases from US tariffs on Chinese suppliers and Russia sanctions, though mitigated by inventory and diversified sourcing.
Persistent generic pricing pressure
Pricing environment in generics remains competitive, limiting value growth despite volume increases. Management noted no easing of pricing pressure.
China export tax rebate withdrawal impact on input costs
China's removal of export tax rebates on certain chemicals may increase raw material costs, though management has diversified 78% of procurement domestically.
Regulatory approval delays for CS commercial volumes
Commercialization of three dedicated CS projects depends on customer regulatory approvals, which could slip beyond the targeted Q3-Q4 CY2027 timeline.
Dependence on a few large CS molecules
While management claims a diversified basket, the three dedicated projects represent significant investment; any single project delay could impact near-term revenue visibility.